Lei Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lei Zheng has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Meng Luo
Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
4 shared publications Guangbo Wu
Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, China
3 shared publicationsGuqing Luo
Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, China
3 shared publicationsMin Chen
Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, China
3 shared publicationsQiang Fan
Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, China
3 shared publicationsZhenghao Wu
Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, China
3 shared publications
Latest Publications
- Open Access
Transcriptome Analysis Reveals the Role of Partial Lymphatic Vessel Ligation in Rats with Cirrhotic Portal Hypertension
The liver lymphatic system plays an essential role during the progression of cirrhotic portal hypertension (PHT), featuring significantly enhanced lymphangiogenesis. However, the role of liver lymphatic functional drainage is understudied in cirrhosis. Therefore, this study aimed to investigate the effects of partial lymphatic vessel ligation (PLVL) of the liver on PHT. The rat model was established by common bile duct ligation (BDL), when PLVL was achieved via ligation of the portal and celiac lymph node. The severity of cirrhosis and PHT were evaluated, as well as macrophage infiltration and lymphangiogenesis. Bulk RNA-seq of liver was used to investigate the underlying mechanisms. Datasets of single-cell and bulk RNA-seq were obtained from the GEO database. Human dermal lymphatic endothelial cells (hLECs) were used for in vitro validation. Ligation of lymphatic drainage caused significant deterioration of liver cirrhosis and PHT in BDL rats. Our bulk RNA-seq suggested significant enrichment of vascular remodeling and angiogenesis-related pathways, as well as lipid metabolism-related biological functions in BDL rats after PLVL. Further analysis combined with public datasets identified several endothelial cell-specific upregulated genes in BDL and PLVL rats. LEC-derived upregulated genes were also identified from bulk RNA-seq of LECs isolated from mice liver, which were validated by incubating hLECs in TNF-α, LPS, TGF-β1. In the current study, we provide the first evidence that liver lymphatic drainage blockade aggravates BDL-induced cirrhotic PHT. LEC-associated secretory proteins might play a potential role in PHT progression, when hepatic inflammation and immune response are considered to be the essential regulatory mechanisms.
Open AccessTranscriptome Analysis Reveals the Role of Partial Lymphatic Vessel Ligation in Rats with Cirrhotic Portal Hypertension
The liver lymphatic system plays an essential role during the progression of cirrhotic portal hypertension (PHT), featuring significantly enhanced lymphangiogenesis. However, the role of liver lymphatic functional drainage is understudied in cirrhosis. Therefore, this study aimed to investigate the effects of partial lymphatic vessel ligation (PLVL) of the liver on PHT. The rat model was established by common bile duct ligation (BDL), when PLVL was achieved via ligation of the portal and celiac lymph node. The severity of cirrhosis and PHT were evaluated, as well as macrophage infiltration and lymphangiogenesis. Bulk RNA-seq of liver was used to investigate the underlying mechanisms. Datasets of single-cell and bulk RNA-seq were obtained from the GEO database. Human dermal lymphatic endothelial cells (hLECs) were used for in vitro validation. Ligation of lymphatic drainage caused significant deterioration of liver cirrhosis and PHT in BDL rats. Our bulk RNA-seq suggested significant enrichment of vascular remodeling and angiogenesis-related pathways, as well as lipid metabolism-related biological functions in BDL rats after PLVL. Further analysis combined with public datasets identified several endothelial cell-specific upregulated genes in BDL and PLVL rats. LEC-derived upregulated genes were also identified from bulk RNA-seq of LECs isolated from mice liver, which were validated by incubating hLECs in TNF-α, LPS, TGF-β1. In the current study, we provide the first evidence that liver lymphatic drainage blockade aggravates BDL-induced cirrhotic PHT. LEC-associated secretory proteins might play a potential role in PHT progression, when hepatic inflammation and immune response are considered to be the essential regulatory mechanisms.
- Open Access
- 7 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1571007
Therapeutic potential of formononetin in cirrhotic portal hypertension: modulating hepatic fibrosis, macrophage polarization, and lymphangiogenesis
Introduction: Formononetin regulates intrahepatic fibrogenesis and macrophage polarization to improve portal pressure and liver function in rats with cirrhotic PHT through SMAD3, STAT1, STAT3 and GSK-3β signaling pathways, and modulates lymphangiogenesis through direct action and macrophage polarization-mediated indirect effects. Formononetin has the potential function of treating cirrhotic PHT.Background and aims: Formononetin (FN) has been reported to have anti-fibrotic effects in the kidneys and anti-M1 polarization effects on macrophages. Lymphangiogenesis is closely associated with macrophages, but its role in cirrhosis and portal hypertension (PHT) remains unclear. This study aims to explore the effects of FN on cirrhotic PHT and the disease-related intrahepatic lymphangiogenesis.Methods: In vivo experiments, bile duct ligation (BDL) induced PHT models were conducted in rats, followed by a 4-week FN treatment (50 mg/kg/day) administered via gavage. Hemodynamics, liver fibrosis, infiltration and polarization of intrahepatic macrophages, as well as intrahepatic lymphangiogenesis, were observed. For in vitro experiments, hepatic stellate cells, macrophages and lymphatic endothelial cells were used to observe the multiple effects of FN.Results: FN significantly ameliorated portal pressure in cirrhosis-induced PHT, improved liver function, and reduced liver fibrosis and hepatic stellate cell activation with decreased SMAD3 protein expression. The intrahepatic macrophage infiltration were markedly decreased, and M1-type macrophage polarization was suppressed by FN, accompanied by inhibition of STAT1, STAT3 and GSK-3β signaling pathways. In PHT models, FN reduced VEGF-C and VEGF-D levels in both the liver and blood, inhibiting intrahepatic lymphangiogenesis in portal area. In vitro, high-dose FN significantly inhibited lymphatic endothelial cell proliferation, while the pro-lymphangiogenic effect of conditioned medium from FN-treated M1 macrophages was diminished.Conclusions: FN significantly ameliorates cirrhotic PHT while reducing fibrosis, suppressing macrophage M1 polarization and inhibiting lymphangiogenesis. This may result from its modulation of multiple signaling pathways (SMAD3, STAT1, STAT3 and GSK-3β).
- 7 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1571007
Open AccessTherapeutic potential of formononetin in cirrhotic portal hypertension: modulating hepatic fibrosis, macrophage polarization, and lymphangiogenesis
Introduction: Formononetin regulates intrahepatic fibrogenesis and macrophage polarization to improve portal pressure and liver function in rats with cirrhotic PHT through SMAD3, STAT1, STAT3 and GSK-3β signaling pathways, and modulates lymphangiogenesis through direct action and macrophage polarization-mediated indirect effects. Formononetin has the potential function of treating cirrhotic PHT.Background and aims: Formononetin (FN) has been reported to have anti-fibrotic effects in the kidneys and anti-M1 polarization effects on macrophages. Lymphangiogenesis is closely associated with macrophages, but its role in cirrhosis and portal hypertension (PHT) remains unclear. This study aims to explore the effects of FN on cirrhotic PHT and the disease-related intrahepatic lymphangiogenesis.Methods: In vivo experiments, bile duct ligation (BDL) induced PHT models were conducted in rats, followed by a 4-week FN treatment (50 mg/kg/day) administered via gavage. Hemodynamics, liver fibrosis, infiltration and polarization of intrahepatic macrophages, as well as intrahepatic lymphangiogenesis, were observed. For in vitro experiments, hepatic stellate cells, macrophages and lymphatic endothelial cells were used to observe the multiple effects of FN.Results: FN significantly ameliorated portal pressure in cirrhosis-induced PHT, improved liver function, and reduced liver fibrosis and hepatic stellate cell activation with decreased SMAD3 protein expression. The intrahepatic macrophage infiltration were markedly decreased, and M1-type macrophage polarization was suppressed by FN, accompanied by inhibition of STAT1, STAT3 and GSK-3β signaling pathways. In PHT models, FN reduced VEGF-C and VEGF-D levels in both the liver and blood, inhibiting intrahepatic lymphangiogenesis in portal area. In vitro, high-dose FN significantly inhibited lymphatic endothelial cell proliferation, while the pro-lymphangiogenic effect of conditioned medium from FN-treated M1 macrophages was diminished.Conclusions: FN significantly ameliorates cirrhotic PHT while reducing fibrosis, suppressing macrophage M1 polarization and inhibiting lymphangiogenesis. This may result from its modulation of multiple signaling pathways (SMAD3, STAT1, STAT3 and GSK-3β).
- Open Access
- 28 February 2025
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 19 (6) , 101487
Activation of AMP-activated Protein Kinase by Metformin Inhibits Dedifferentiation of Platelet-derived Growth Factor-BB-induced Vascular Smooth Muscle Cells to Improve Arterial Remodeling in Cirrhotic Portal Hypertension
- 28 February 2025
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 19 (6) , 101487
Open AccessActivation of AMP-activated Protein Kinase by Metformin Inhibits Dedifferentiation of Platelet-derived Growth Factor-BB-induced Vascular Smooth Muscle Cells to Improve Arterial Remodeling in Cirrhotic Portal Hypertension
- 27 December 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 964, 176278
Cediranib ameliorates portal hypertensive syndrome via inhibition of VEGFR-2 signaling in cirrhotic rats
- 27 December 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 964, 176278
Cediranib ameliorates portal hypertensive syndrome via inhibition of VEGFR-2 signaling in cirrhotic rats